1240 related articles for article (PubMed ID: 18847555)
1. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
2. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
3. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.
Arbyn M; Sasieni P; Meijer CJ; Clavel C; Koliopoulos G; Dillner J
Vaccine; 2006 Aug; 24 Suppl 3():S3/78-89. PubMed ID: 16950021
[TBL] [Abstract][Full Text] [Related]
4. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.
Cox JT;
Arch Pathol Lab Med; 2003 Aug; 127(8):950-8. PubMed ID: 12952506
[TBL] [Abstract][Full Text] [Related]
5. Chapter 10: New dimensions in cervical cancer screening.
Cuzick J; Mayrand MH; Ronco G; Snijders P; Wardle J
Vaccine; 2006 Aug; 24 Suppl 3():S3/90-7. PubMed ID: 16950022
[TBL] [Abstract][Full Text] [Related]
6. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
7. Screening for cervical cancer: new alternatives and research.
Lörincz AT
Salud Publica Mex; 2003; 45 Suppl 3():S376-87. PubMed ID: 14746031
[TBL] [Abstract][Full Text] [Related]
8. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds.
Tropé A; Sjøborg KD; Nygård M; Røysland K; Campbell S; Alfsen GC; Jonassen CM
J Clin Microbiol; 2012 Jun; 50(6):1927-35. PubMed ID: 22518869
[TBL] [Abstract][Full Text] [Related]
9. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.
Lazcano-Ponce E; Lorincz AT; Cruz-Valdez A; Salmerón J; Uribe P; Velasco-Mondragón E; Nevarez PH; Acosta RD; Hernández-Avila M
Lancet; 2011 Nov; 378(9806):1868-73. PubMed ID: 22051739
[TBL] [Abstract][Full Text] [Related]
10. [Use of high-risk human papillomavirus DNA testing to deal with atypical squamous cells undetermined significance and low squamous intraepithelial lesion].
Guo YL; You K; Geng L; Zhang XW; Shen XY; Yao YJ; Fan XH
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):480-2. PubMed ID: 17068618
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
[TBL] [Abstract][Full Text] [Related]
12. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1.
Jordan J; Arbyn M; Martin-Hirsch P; Schenck U; Baldauf JJ; Da Silva D; Anttila A; Nieminen P; Prendiville W
Cytopathology; 2008 Dec; 19(6):342-54. PubMed ID: 19040546
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.
Monsonego J; Zerat L; Syrjänen K; Zerat JC; Smith JS; Halfon P
Vaccine; 2012 Jul; 30(35):5215-21. PubMed ID: 22713720
[TBL] [Abstract][Full Text] [Related]
14. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
15. [A study of cervical cancer screening algorithms].
Zhao FH; Zhang WH; Pan QJ; Zhang X; Chen W; Liu B; Ma JF; Hu SY; Qiao YL
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):420-4. PubMed ID: 20819481
[TBL] [Abstract][Full Text] [Related]
16. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.
Verdoodt F; Szarewski A; Halfon P; Cuschieri K; Arbyn M
Cancer Cytopathol; 2013 Dec; 121(12):675-87. PubMed ID: 23881840
[TBL] [Abstract][Full Text] [Related]
17. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.
Katki HA; Kinney WK; Fetterman B; Lorey T; Poitras NE; Cheung L; Demuth F; Schiffman M; Wacholder S; Castle PE
Lancet Oncol; 2011 Jul; 12(7):663-72. PubMed ID: 21684207
[TBL] [Abstract][Full Text] [Related]
18. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy.
Arbyn M; Roelens J; Cuschieri K; Cuzick J; Szarewski A; Ratnam S; Reuschenbach M; Belinson S; Belinson JL; Monsonego J
Int J Cancer; 2013 Jan; 132(1):101-8. PubMed ID: 22610699
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test.
Benevolo M; Vocaturo A; Caraceni D; French D; Rosini S; Zappacosta R; Terrenato I; Ciccocioppo L; Frega A; Giorgi Rossi P
J Clin Microbiol; 2011 Jul; 49(7):2643-50. PubMed ID: 21525231
[TBL] [Abstract][Full Text] [Related]
20. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China.
Zhao FH; Lin MJ; Chen F; Hu SY; Zhang R; Belinson JL; Sellors JW; Franceschi S; Qiao YL; Castle PE;
Lancet Oncol; 2010 Dec; 11(12):1160-71. PubMed ID: 21075054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]